Stock Code: PVA
Listing Date: 2008-06-12 00:00:00
Website: http://www.psivida.com
Industry: Classification Pending
Principal Activities:
The Company is the successor entity to pSivida Limited (ASX code: PVA), an ASX listed pharmaceutical and biotechnology development company which undertook a restructure by way of scheme of arrangement resulting in it becoming a wholly owned subsidiary of the Company, thereby re-domiciling to the USA.
Address:
101 Collins Street, Level 37, c/- Blake Dawson
MELBOURNE
VIC 3000
Phone: (08) 9227 8327
Fax: (08) 9227 6838
Executives & Directors
Dr David Mazzo, Non Exec. Chairman
Dr Paul Ashton, President, Managing Director, CEO
Mr Paul Hopper, Director
Mr Michael Rogers, Director
Mr Peter Savas, Director
Mr Len Ross, Finance Director
Ms Lori Freedman, General Counsel
Mr Brian Leedman, Investor Relations
Mr Charles Baird, Local Agent
Ms Lori Freedman, Secretary
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
![]()
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
| Company (Stock code) | Date/time Dates subject to change |
Event Display audio events only |
|---|
| PSIVIDA CORP. (PVA) | Wed, 8 Feb 2012 | Quarterly Production Date | |
| PSIVIDA CORP. (PVA) | Wed, 8 Feb 2012 | Quarterly Sales Date | |
| PSIVIDA CORP. (PVA) | Tue, 29 Nov 2011 | Annual General Meeting | |
| PSIVIDA CORP. (PVA) | Wed, 14 Sep 2011 | Full Year Results | |
| PSIVIDA CORP. (PVA) | Tue, 10 May 2011 | Quarterly Sales Date | |
| PSIVIDA CORP. (PVA) | Fri, 11 Feb 2011 | Interim Results | |
| PSIVIDA CORP. (PVA) | Thu, 3 Feb 2011 | EGM | |
| PSIVIDA CORP. (PVA) | Thu, 3 Feb 2011 | Quarterly Production Date | |
| PSIVIDA CORP. (PVA) | Mon, 13 Dec 2010 | Annual General Meeting | |
| PSIVIDA CORP. (PVA) | Thu, 23 Sep 2010 | Quarterly Sales Date | |
| PSIVIDA CORP. (PVA) | Wed, 17 Feb 2010 12:15pm |
pSivida 2Q Results |